🔺 What to do when markets are at an all-time high? Find smart bargains, like these.See Undervalued Stocks

Lenz Therapeutics' eye drop helps improve vision in late-stage study

Published 04/03/2024, 07:49 AM
Updated 04/03/2024, 10:22 AM
© Reuters.

(Reuters) -Lenz Therapeutics said on Wednesday its lead experimental drug being tested in patients with a common age-related eye disorder showed improvement in nearsightedness in a late-stage study.

Shares of the company, which gained as much as 17% earlier in the day, were last trading 4.2% higher at $21.89.

The once-daily eye drop, LNZ100, is being tested to treat presbyopia, which causes inability to focus on near objects and affects an estimated 128 million people in the United States, according to the company.

Its treatment options include wearing reading glasses, contact lenses and refractive surgery. Abbvie's Vuity bagged the U.S. FDA approval in 2021 as the first eye drop for presbyopia. Companies such as Eyenovia (NASDAQ:EYEN) and Ocuphire Pharma are also developing treatments for the disease.

The late-stage study testing Lenz's eye drop comprised two six-week efficacy trials and a six-month safety trial. The trials enrolled a total of 1,059 participants ranging from ages 45 to 75 years.

The treatment helped improve near vision without impacting distant vision for 71% of the patients at three hours post-treatment.

Based on the trial, the San Diego, California-based company plans to submit a U.S. marketing application for LNZ100 in mid-2024.

Lenz said its another drug, LNZ101, also showed similar results but did not show superiority to LNZ100.

Rival Eyenovia is testing its drug delivery device Optejet in late-stage trials with its experimental drug to treat presbyopia. Ocuphire is also testing its eye drop in a late-stage trial.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.